Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma

Acta Oncol. 2016;55(3):382-5. doi: 10.3109/0284186X.2015.1080858. Epub 2015 Sep 12.

Authors

Finn Ole Larsen¹, Dan Taksony Solyom Hoegdall¹, Estrid Hoegdall², Dorte Nielsen¹

Affiliations

¹ a Department of Oncology , Herlev and Gentofte Hospital, University of Copenhagen , Copenhagen , Denmark and.
² b Department of Pathology , Herlev and Gentofte Hospital, University of Copenhagen , Copenhagen , Denmark.

PMID: 26364518
DOI: 10.3109/0284186X.2015.1080858

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biliary Tract Neoplasms / drug therapy*
Biliary Tract Neoplasms / pathology
Capecitabine / administration & dosage
Cetuximab / administration & dosage
Deoxycytidine / administration & dosage
Deoxycytidine / analogs & derivatives
Female
Follow-Up Studies
Gemcitabine
Humans
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy*
Neoplasm Recurrence, Local / pathology
Neoplasm Staging
Organoplatinum Compounds / administration & dosage
Oxaliplatin
Prognosis
Prospective Studies
Survival Rate
Young Adult

Substances

Organoplatinum Compounds
Oxaliplatin
Deoxycytidine
Capecitabine
Cetuximab
Gemcitabine